 |
|
Interaction of PhXA41, a New Prostaglandin Analogue, With PilocarpineA Study on Patients With Elevated Intraocular Pressure
Björn Friström, MD;
Sven Erik G. Nilsson, MD, PhD
Arch Ophthalmol. 1993;111(5):662-665.
Abstract
| |
• Objective.
—To evaluate the effects of PhXA41, a new prostaglandin analogue, on the intraocular pressure (IOP) in patients receiving pilocarpine treatment and the effects of pilocarpine in patients receiving PhXA41 treatment.
Design.
—Twenty patients with ocular hypertension were randomized into two parallel groups. The treatment period was 2 weeks. Ten patients in group 1 were given PhXA41 twice daily during week 1 and, in addition, pilocarpine three times daily during week 2. Ten patients in group 2 received pilocarpine three times daily during week 1 and PhXA41 twice daily in addition during week 2. PhXA41 was used in a concentration of 0.006%, and pilocarpine was given in a concentration of 2%.
Main Outcome Measures.
—In group 1, the mean IOP on day 0 was 25.1 mm Hg; on day 7,19.1 mm Hg; and on day 14,17.6 mm Hg. In group 2, the mean IOP on day 0 was 23.8 mm Hg; on day 7,20.4 mm Hg; and on day 14,17.7 mm Hg.
Results.
—PhXA41 had a clinically significant IOP-lowering effect (23.4% reduction on day 7 as compared with baseline day (P<.001). The corresponding value with pilocarpine was 14.3% (P<.001). When pilocarpine was added to PhXA41, the additional IOP reduction was 7.4% (P<.01) compared with 14.2% (P<.01) when PhXA41 was added to pilocarpine. The two groups were found to have an almost equal reduction in IOP on day 14 (group 1,29.4%; group 2, 26.6%). No serious adverse reactions were seen. Some conjunctival hyperemia in the PhXA41-treated eyes was noted on day 7, as compared with the pilocarpine-treated eyes, but there were few complaints of discomfort.
Conclusions.
—This study indicated that PhXA41 could be useful in the treatment of glaucoma, as monotherapy, or in certain cases in combination with pilocarpine.
Author Affiliations
From the Department of Ophthalmology, University of Linköping (Sweden). The authors have no commercial or proprietary interest in the PhXA41 eyedrops.
Footnotes
Accepted for publication February 5, 1993.
Reprint requests to Department of Ophthalmology, University of Linköping, S-581 85 Linköping, Sweden (Dr Friström).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A 5-Year, Multicenter, Open-Label, Safety Study of Adjunctive Latanoprost Therapy for Glaucoma
Alm et al.
Arch Ophthalmol 2004;122:957-965.
ABSTRACT
| FULL TEXT
Additive effect of unoprostone and latanoprost in patients with elevated intraocular pressure
Aung et al.
Br J Ophthalmol 2002;86:75-79.
ABSTRACT
| FULL TEXT
From PGF2{{alpha}}-Isopropyl Ester to Latanoprost: A Review of the Development of Xalatan The Proctor Lecture
Stjernschantz
IOVS 2001;42:1134-1145.
FULL TEXT
Medical Management of Glaucoma
Alward
NEJM 1998;339:1298-1307.
FULL TEXT
Effect of latanoprost on intraocular pressure in patients with glaucoma on maximal tolerated medical treatment
AZUARA-BLANCO et al.
Br J Ophthalmol 1997;81:1115b-1115.
FULL TEXT
A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension
Fristrom and Nilsson
Br J Ophthalmol 1997;81:867-870.
ABSTRACT
| FULL TEXT
Latanoprost and Physostigmine Have Mostly Additive Ocular Hypotensive Effects in Human Eyes
Linden and Alm
Arch Ophthalmol 1997;115:857-861.
ABSTRACT
|
